8-K: Freenome's CRC Blood Test Gets FDA Approval, Abbott to Commercialize

Freenome's SimpleScreen CRC blood-based screening test for colorectal cancer has received FDA approval, with Abbott set to commercialize it in the U.S.

Summary

• Freenome, Inc. announced on July 27, 2026, that the U.S. Food and Drug Administration (FDA) has approved its SimpleScreen CRC blood-based screening test for colorectal cancer (CRC).
• The test is for adults aged 45 and older at average risk for CRC and detects signals associated with colorectal cancer from cell-free DNA in the blood.
• Abbott will exclusively commercialize SimpleScreen CRC in the U.S. under a commercial agreement signed in August 2025.
• Freenome will receive a $100 million milestone payment from Abbott for this FDA approval.
• The PREEMPT CRC study, which evaluated SimpleScreen CRC, enrolled over 48,000 asymptomatic, average-risk adults.
• In the study, SimpleScreen CRC demonstrated 81.1% sensitivity for detecting colorectal cancer and 90.4% specificity for advanced colorectal neoplasia.
• The FDA approval means SimpleScreen CRC meets Medicare coverage criteria and is expected to be incorporated into American Cancer Society guidelines.
• This approval marks the first commercial milestone for Freenome's Personalized Cancer Detection approach.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, driven by FDA approval, a significant milestone payment, and strong clinical validation, positioning the company for commercial success.

Positives

• FDA approval of SimpleScreen CRC, a new blood-based screening option for colorectal cancer.
• Abbott's exclusive U.S. commercialization agreement, leveraging their existing CRC infrastructure and expertise.
• A $100 million milestone payment to Freenome from Abbott upon FDA approval.
• SimpleScreen CRC demonstrated 81.1% sensitivity for colorectal cancer and 90.4% specificity for advanced colorectal neoplasia in the PREEMPT CRC study.
• The test is expected to expand access to CRC screening for up to 60 million Americans overdue for screening.
• FDA approval facilitates Medicare coverage and expected inclusion in American Cancer Society guidelines.
• Represents the first commercial milestone for Freenome's Personalized Cancer Detection strategy.

Negatives

• The test's sensitivity for advanced precancerous lesions (APLs) was 13.7%, with 30.7% for APLs with high-grade dysplasia, indicating room for improvement in detecting these specific lesions.
• While sensitive for cancer, the test is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.

Risks

• Risks related to the approval of Freenome's products and tests and the timing of expected regulatory and business milestones.
• Ability to negotiate definitive contractual arrangements with potential customers.
• Impact of competitive products and tests in the market.
• Ability to obtain sufficient supply of materials.
• Ability to obtain additional financing.
• Ability to attract and retain qualified personnel.
• Global economic and political conditions.
• Legal and regulatory changes.

Future Outlook

Freenome plans to incorporate SimpleScreen CRC into its broader SimpleScreen portfolio and continue advancing additional singleand multi-cancer tests built on its multiomics platform. The partnership with Abbott is expected to expand access to blood-based CRC screening in the U.S.

Management Comments

• "Today's approval is an important validation of the scientific vision we've spent more than a decade building," said Aaron Elliott, Ph.D., CEO of Freenome. "SimpleScreen CRC is the first commercial realization of our Personalized Cancer Detection strategy, built on base-level cfDNA methylation and AI enhanced accuracy. We believe this common technology foundation will power our expanding portfolio of cancer screening tests, continuous performance improvements and future product generations as our platform continues to learn."
• "FDA approval is a significant milestone in our mission to help more people get screened, detect colorectal cancer earlier and ultimately help save lives," said Jake Orville, senior vice president of Abbott's cancer diagnostics business. "No single screening option will reach every patient. By adding SimpleScreen CRC alongside Cologuard, we are expanding the choices available to healthcare providers and helping remove barriers that keep too many people from getting screened."
• "The most effective screening test is the one a person will actually complete," said Aasma Shaukat, M.D., M.P.H., professor of medicine at NYU Grossman School of Medicine and a co-lead principal investigator on the PREEMPT CRC study. "Many people who should be screened for colorectal cancer simply aren't. A blood-based test provides another way to reach unscreened patients, and bringing more people into the screening fold leads to earlier detection and better outcomes."

Industry Context

StockSavvy.ai notes that the FDA approval of Freenome's SimpleScreen CRC test, coupled with Abbott's commercialization efforts, signifies a significant advancement in the competitive landscape of early cancer detection. This development aligns with the broader industry trend towards less invasive, more accessible screening methods, particularly for prevalent cancers like colorectal cancer, and highlights the growing role of AI/ML in diagnostic technologies.

Comparison to Industry Standards

• The sensitivity of 81.1% for colorectal cancer detection by SimpleScreen CRC is competitive within the field of blood-based cancer screening tests.
• The specificity of 90.4% for advanced colorectal neoplasia is a key metric for minimizing false positives, a critical factor for widespread adoption.
• The PREEMPT CRC study's enrollment of over 48,000 participants is substantial, providing robust clinical validation, which is a high standard in the diagnostics industry.
• The integration with Medicare coverage and potential inclusion in American Cancer Society guidelines are crucial benchmarks for market acceptance and clinical utility, similar to established diagnostic tests.

Stakeholder Impact

• Shareholders: Potential for increased company valuation and future revenue streams due to commercialization and milestone payment.
• Patients: Expanded access to a less invasive screening option for colorectal cancer, potentially leading to earlier detection and improved outcomes.
• Healthcare Providers: A new diagnostic tool to offer patients, potentially improving screening rates and patient management.
• Abbott: Expansion of their diagnostics portfolio with a novel blood-based CRC test, leveraging existing infrastructure and market presence.

Next Steps

• Abbott to commercialize SimpleScreen CRC in the U.S. starting this fall.
• Freenome to receive a $100 million milestone payment from Abbott.
• SimpleScreen CRC expected to be incorporated into American Cancer Society guidelines.
• Freenome plans to incorporate SimpleScreen CRC into its broader SimpleScreen portfolio.
• Freenome will continue to advance additional singleand multi-cancer tests.

Key Dates

Recommendation

The FDA approval of a key diagnostic test, coupled with a substantial milestone payment and a strategic commercialization partnership with Abbott, represents a significant de-risking event and a strong catalyst for future growth. The test's demonstrated clinical efficacy and expected market penetration, including Medicare coverage, suggest a high probability of commercial success and positive financial impact.

Keywords

colorectal cancer screening, blood test, FDA approval, SimpleScreen CRC, Freenome, Abbott, early cancer detection, cfDNA